Study Evaluating the Safety and Tolerability of L-377202

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00987753
First received: September 30, 2009
Last updated: June 25, 2010
Last verified: June 2010

September 30, 2009
June 25, 2010
March 1999
September 2000   (final data collection date for primary outcome measure)
Evaluation of the administration of L-377202 every three weeks in patients with hormone refractory prostate cancer [ Time Frame: Every 3 weeks until disease progression or unacceptable toxicity ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00987753 on ClinicalTrials.gov Archive Site
Evaluation of the radiologic and/or PSA responses to L-377202 treatment [ Time Frame: Every 3 weeks until disease progression or unacceptable toxicity ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study Evaluating the Safety and Tolerability of L-377202
A PhaseI/II Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of L-377202 Administered Once Every 3 Weeks

The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of L-377202 including the dose-limiting adverse effects of treatment with L-377202, and (3) assess the pharmacokinetics of various doses of L-377202 and the plasma profile of liberated doxorubicin and leu-doxorubicin.

This is an open, nonrandomized, rising-dose study in patients with hormone refractory prostate cancer. Patients will be treated with L-377202 once every three weeks. Plasma concentrations of L-377202, liberated doxorubicin, and leu-doxorubicin will be obtained at defined time intervals throughout the study. At least 1 patient will be treated at each dose level until there is evidence of greater than or equal to Grade 2 drug-related toxicity. Each patient will be treated at only 1 dose level, although multiple cycles may be administered until signs of disease progression or unacceptable toxicity are evident. Doses will be doubled for each subsequent cohort of patients until evidence of greater than or equal to Grade 2 drug-related toxicity. Upon documentation of greater than or equal to Grade 2 drug-related toxicity, subsequent dose escalations will proceed along the modified Fibonacci scale and enroll at least 3 patients per dose level until 1 patient experiences dose-limiting toxicity (DLT).

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hormone Refractory Prostate Cancer
  • Prostate Cancer
Drug: L-377202
For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
Experimental: infusion of L-377202
Intervention: Drug: L-377202
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
13
November 2001
September 2000   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is at least an 18-year-old male and has histologically documented, progressive carcinoma of the prostate which is refractory to hormonal manipulation. Progressive disease may be documented by new lesions on bone scan, increase in radiologically measurable disease, or an increase in PSA (at least 50% increase from nadir confirmed twice and measured at least 2 weeks apart.)
  • An appropriate interval of time has passed since alteration of any hormonal therapy (e.g., 4 weeks for steroids, LHRH agonists, flutamide or megestrol acetate and 6 weeks for nilutamide and bicalutamide).
  • Patient has a serum PSA of 20 ng/mL or higher.
  • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Patients has a life expectancy of >3 months.
  • Patient understands and agrees to participate in the study by providing written informed consent.

Exclusion Criteria:

  • Patient is mentally or legally incapacitated at the time of the study or has a history (less than 5 years prior to entry) of drug or alcohol abuse or is currently a user (including "recreational use") of any illicit drugs.
  • Patient has known HIV or a known HIV-related malignancy.
  • Patient has participated in another study (including FDA approved drugs for a non-FDA approved indication) of an investigational agent within the last 4 weeks.
  • Patient requires treatment or is anticipated to require treatment with Cyclosporine, Phenobarbital, phenytoin, or streptozocin.
  • Patient has received tumor directed immunologic therapy, radiation therapy, surgery, or chemotherapy within 4 weeks of the study. However, patients who are receiving thyroid replacement therapy may be included. For mitomycin or nitrosourea, there must be a 6-week treatment free interval.
  • Patient has received strontium treatment within 12 weeks prior to treatment.
  • Patient is anticipated to require immunologic therapy, radiation therapy, surgery, or chemotherapy during the study.
  • Patient has received high-dose chemotherapy with stem cell rescue.
  • Patient has a history of significant cardiac dysrhythmias (Grade 3 or higher excluding atrial fibrillation).
  • Patient has recently had (within 6 months) a myocardial infarction, unstable angina, or congestive heart failure.
  • Patient has an abnormal PT (INR) or a PTT (>1.2 times normal). Low-dose warfarin (1 to 2 mg P.O. q.d.) or heparin (the equivalent of 5000 IU SQ b.i.d.) administered to maintain catheter patency is acceptable. Patients administered higher doses of anticoagulants may be considered on an individual basis pending discussion between the clinical monitor and investigator. Such patients will require more intensive monitoring of PT (INR) and aPTT (at least every other day).
  • Patient has an absolute neutrophil count <1500/mm3 or platelet count <100,000/mm3 or hemoglobin <9 gm/dL, bilirubin >1.5 times normal or ALT or AST >2.5 times normal or creatinine >1.5 times normal.
  • Patient has an active infection.
  • Patient has an active (edema, progressive disease, or clinical neurologic symptoms) metastatic CNS lesion.
  • Patient has received the equivalent of >180 mg/m2 of doxorubicin or >40 mg/m2 mitoxantrone.
  • Patient has left ventricular ejection fraction (LVEF) <45%.
  • Patient has received radiation to >25% of his total bone marrow.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00987753
F990224004, UAB 9902
Yes
Andres Forero, M.D., University of Alabama at Birmingham
University of Alabama at Birmingham
Merck Sharp & Dohme Corp.
Principal Investigator: John Rinehart, M.D. University of Alabama at Birmingham (no longer employee)
Principal Investigator: Scot Ebbinghaus, M.D. University of Alabama at Birmingham (no longer employee)
University of Alabama at Birmingham
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP